Hevolution announces $20 million impact investment to advance promising aging therapies

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Foundation leads a $50 million Series A Extension in Aeovian Pharmaceuticals to advance therapies that target mTORC1 biological pathway.

Hevolution Foundation today announced an investment of $20 million as the lead investor for a $50 million Series A financing extension in Aeovian Pharmaceuticals.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2015

Aeovian Pharmaceuticals

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing highly selective small-molecule therapeutics that modulate the mTORC1 pathway to restore cellular metabolic quality control. The company targets dysregulated growth and hyperactive signaling in rare genetic and age-related diseases, with its lead candidate AV078 currently in Phase 1 trials for tuberous sclerosis complex refractory epilepsy. Aeovian's proprietary platform encompasses both mTORC1 and CD38 inhibitors designed to address underlying disease mechanisms while minimizing off-target effects. The company's mission centers on translating fundamental aging biology into therapeutic interventions that improve healthspan and address unmet medical needs in rare and age-related conditions.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE